Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12494815 | 0.96 | ALDH1A1 (0.54) | ALDH1A1HPGDRAB9ANPC1HCAR3 | |
| SCHEMBL9944747 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HPGDRAB9ANPC1HCAR3 | |
| SCHEMBL9945003 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HPGDRAB9ANPC1HCAR3 | |
| SCHEMBL9945024 | 0.88 | ALDH1A1 (0.47) | ALDH1A1HPGDRAB9ANPC1TAS1R3 | |
| SCHEMBL9945014 | 0.88 | ALDH1A1 (0.47) | ALDH1A1HPGDRAB9ANPC1TAS1R3 | |
| SCHEMBL12495181 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HCAR3MAPTHTTL3MBTL1 | |
| SCHEMBL12494909 | 0.81 | ALDH1A1 (0.59) | ALDH1A1HPGDRAB9ANPC1HCAR3 | |
| SCHEMBL17937204 | 0.81 | LMNA (0.43) | ALDH1A1SMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL16882061 | 0.80 | HCAR3 (0.49) | ALDH1A1HPGDRAB9ANPC1HCAR3 | |
| SCHEMBL9945010 | 0.80 | ALDH1A1 (0.45) | ALDH1A1HPGDRAB9ANPC1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | ALDH1A1 126/4885HPGD 20/4885RAB9A 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.